Clinical Research of Philadelphia

Executive Summary

Clinical Research of Philadelphia is a private clinical research site established in 1996, specializing in conducting trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and other metabolic conditions. With over two decades of experience, the site has supported numerous Phase I-IV studies, contributing to the evolving landscape of fatty liver disease treatment. The recent renaming of NAFLD to MASLD reflects a shift in understanding that the site has been at the forefront of, helping sponsors navigate regulatory and patient engagement changes. As a dedicated clinical site, its performance is tied to enrollment rates and successful trial execution. Given the global prevalence of MASLD, the site is well-positioned to benefit from increased research investment. However, as a contract research organization, its growth is dependent on sponsor demand and competitive positioning.

Upcoming Catalysts (preview)

• Q3 2026Enrollment completion for a Phase 2 MASLD trial75% success
• 2026Strategic partnership with a top-20 pharmaceutical company50% success
• Q4 2026FDA advisory committee meeting for a MASLD drug in which the site participated30% success